CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sept. 13, 2006--Idera Pharmaceuticals, Inc. (AMEX: IDP) today announced the issuance of US patent 7,105,495 (the '495 patent) for immune modulatory oligonucleotides (IMO(TM)) that target Toll-like Receptor 9 (TLR9). The claims of this patent cover methods for modulating the immunostimulatory effect of novel dinucleotide motifs and CpG motifs by introducing modifications in the flanking sequence. These modifications include changes to the backbone and the nucleosides. Similar claims have been granted in Europe (EU 1,278,761) and Australia (AU 2001257366).
